---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-020366"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T09:47:52.838580+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Q4 net loss $12.8M, cash $170M; ADVANCED-2 12-month data by mid-2025

## Summary
- Cash and equivalents $170.3M as of Dec 31, 2024, funded into 2027 after $100M public offering.
- Full year 2024 net loss $44.6M ($2.17/share) vs $40.4M ($3.57/share) in 2023.
- ADVANCED-2 trial: 12-month data from evaluable NMIBC patients expected by mid-2025; 72% CR at 6 months reported.
- THRIVE-3 registrational trial of IV Choline Chloride to start in 1H 2025; FDA Fast Track granted.
- STARBORN-1 interim update for TARA-002 in pediatric LMs expected by end of 1H 2025.

## SEC filing metadata
- accession: 0001213900-25-020366
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/0001213900-25-020366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea0232641-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-020366
- JSON: https://secwatch.observer/filing/0001213900-25-020366.json
- Plain text: https://secwatch.observer/filing/0001213900-25-020366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.